Identification of molecularly targeted therapy-induced immunopeptidome in diffuse midline glioma (DMG)
MTX-241F changes the glioma immunopeptidome, unveiling H2B1K, brain-enriched, and treatment-induced immunopeptides as immunologically visible targets. These findings provide a rationale for integrating molecularly targeted therapy with immunotherapeutic approaches to enhance tumor recognition and treatment efficacy in DMG and GBM.
Authors
- Stefanie Galbán (ORCID: https://orcid.org/0000-0001-5012-7614)
- Julie M. Rumble (ORCID: https://orcid.org/0000-0001-7220-7631)
- Mostafa M.H. Ibrahim (ORCID: https://orcid.org/0000-0003-2038-9933)
- Seeta Nyayapathy
- Habeebah Olufe Owolabi
- Arun Everest-Dass
- Christopher E. Whitehead
- Richard H. Jones
- Judith S. Sebolt-Leopold
- Ali Namvar
- Niloofar Khairkhah
Institutions
- Griffith University (AU)
- University of Michigan (US)
- BioWorks (United States) (US)
- Cayman Chemical (United States) (US)
- Michigan Medicine (US)
Publication Details
- Journal
- Neoplasia
- Published
- 2026-02-04
- DOI
- https://doi.org/10.1016/j.neo.2026.101278
- Primary Topic
- Glioma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00